Neuraceq, or florbetaben F18 injection, can help estimate the density of neuritic plaque in the brain for patients who are under evaluation for Alzheimer’s disease or other forms of cognitive decline, according to the news release.
If a Neuraceq scan shows little to no neuritic plaque, it indicates a lesser likelihood that the patient’s cognitive impairment is due to Alzheimer’s, according to the news release.
While the imaging agent “does not establish the diagnosis of AD or any other cognitive disorder,” it’s estimation of neuritic plaque density is a tool to help physicians determine an eventual diagnosis, according to the release.
More Articles on FDA Approvals:
FDA Approves Implantable Device for Certain Type of Hearing Loss
FDA Approves Apixaban for New Use
FDA Approves Migraine ‘Headband’ for Marketing
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
